NO20016255D0 - Kromeno[4,3,2-de]isoquinoline som potente dopamineresepter ligander - Google Patents
Kromeno[4,3,2-de]isoquinoline som potente dopamineresepter liganderInfo
- Publication number
- NO20016255D0 NO20016255D0 NO20016255A NO20016255A NO20016255D0 NO 20016255 D0 NO20016255 D0 NO 20016255D0 NO 20016255 A NO20016255 A NO 20016255A NO 20016255 A NO20016255 A NO 20016255A NO 20016255 D0 NO20016255 D0 NO 20016255D0
- Authority
- NO
- Norway
- Prior art keywords
- improving
- treating
- compounds
- dopamine receptor
- receptor ligands
- Prior art date
Links
- 102000015554 Dopamine receptor Human genes 0.000 title abstract 3
- 108050004812 Dopamine receptor Proteins 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
- 230000003389 potentiating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000009084 cardiovascular function Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 210000000750 endocrine system Anatomy 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Silicon Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14016699P | 1999-06-21 | 1999-06-21 | |
| PCT/US2000/016857 WO2000078765A2 (en) | 1999-06-21 | 2000-06-20 | CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20016255D0 true NO20016255D0 (no) | 2001-12-20 |
| NO20016255L NO20016255L (no) | 2001-12-20 |
Family
ID=22490027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016255A NO20016255L (no) | 1999-06-21 | 2001-12-20 | Kromeno[4,3,2-de]isoquinoline som potente dopamineresepter ligander |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6413977B1 (no) |
| EP (1) | EP1192161B1 (no) |
| JP (1) | JP2003502428A (no) |
| KR (1) | KR20020010716A (no) |
| AT (1) | ATE240959T1 (no) |
| AU (2) | AU4536599A (no) |
| BR (1) | BR0011711A (no) |
| CA (1) | CA2373497A1 (no) |
| DE (1) | DE60002867T2 (no) |
| DK (1) | DK1192161T3 (no) |
| ES (1) | ES2199837T3 (no) |
| MX (1) | MXPA01013229A (no) |
| NO (1) | NO20016255L (no) |
| NZ (1) | NZ515613A (no) |
| PT (1) | PT1192161E (no) |
| WO (1) | WO2000078765A2 (no) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082567A2 (en) * | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| WO2005062894A2 (en) * | 2003-12-23 | 2005-07-14 | Darpharma, Inc. | Co-administration of dopamine-receptor binding compounds |
| WO2007098462A2 (en) * | 2006-02-21 | 2007-08-30 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
| US9359303B2 (en) | 2009-04-21 | 2016-06-07 | Purdue Research Foundation | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK297275A (da) * | 1974-08-07 | 1976-02-08 | Aspro Nicholas Ltd | Isoquinolinderivater |
| CA1270253A (en) * | 1981-06-18 | 1990-06-12 | John L. Neumeyer | R(-)-10,11-alkylenedioxy-n-alkylnorapomorphine |
| US5635506A (en) * | 1990-06-26 | 1997-06-03 | Research Corporation Technologies, Inc. | 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
-
1999
- 1999-06-21 AU AU45365/99A patent/AU4536599A/en not_active Abandoned
-
2000
- 2000-06-20 CA CA002373497A patent/CA2373497A1/en not_active Abandoned
- 2000-06-20 AT AT00942943T patent/ATE240959T1/de not_active IP Right Cessation
- 2000-06-20 KR KR1020017016235A patent/KR20020010716A/ko active IP Right Grant
- 2000-06-20 DK DK00942943T patent/DK1192161T3/da active
- 2000-06-20 BR BR0011711-0A patent/BR0011711A/pt not_active IP Right Cessation
- 2000-06-20 ES ES00942943T patent/ES2199837T3/es not_active Expired - Lifetime
- 2000-06-20 EP EP00942943A patent/EP1192161B1/en not_active Expired - Lifetime
- 2000-06-20 WO PCT/US2000/016857 patent/WO2000078765A2/en active IP Right Grant
- 2000-06-20 NZ NZ515613A patent/NZ515613A/xx unknown
- 2000-06-20 MX MXPA01013229A patent/MXPA01013229A/es active IP Right Grant
- 2000-06-20 AU AU57492/00A patent/AU777522C/en not_active Ceased
- 2000-06-20 DE DE60002867T patent/DE60002867T2/de not_active Expired - Fee Related
- 2000-06-20 JP JP2001504931A patent/JP2003502428A/ja not_active Withdrawn
- 2000-06-20 PT PT00942943T patent/PT1192161E/pt unknown
- 2000-06-21 US US09/598,127 patent/US6413977B1/en not_active Expired - Lifetime
-
2001
- 2001-12-20 NO NO20016255A patent/NO20016255L/no not_active Application Discontinuation
-
2002
- 2002-07-02 US US10/188,579 patent/US6916832B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT1192161E (pt) | 2003-09-30 |
| EP1192161A2 (en) | 2002-04-03 |
| ES2199837T3 (es) | 2004-03-01 |
| CA2373497A1 (en) | 2000-12-28 |
| AU4536599A (en) | 2001-01-09 |
| US6413977B1 (en) | 2002-07-02 |
| US6916832B2 (en) | 2005-07-12 |
| AU777522B2 (en) | 2004-10-21 |
| DE60002867D1 (de) | 2003-06-26 |
| DE60002867T2 (de) | 2004-02-26 |
| WO2000078765A2 (en) | 2000-12-28 |
| ATE240959T1 (de) | 2003-06-15 |
| WO2000078765A3 (en) | 2001-06-28 |
| MXPA01013229A (es) | 2002-11-04 |
| NZ515613A (en) | 2004-03-26 |
| AU777522C (en) | 2005-07-28 |
| KR20020010716A (ko) | 2002-02-04 |
| US20050080266A1 (en) | 2005-04-14 |
| EP1192161B1 (en) | 2003-05-21 |
| JP2003502428A (ja) | 2003-01-21 |
| DK1192161T3 (da) | 2003-08-25 |
| BR0011711A (pt) | 2002-03-26 |
| AU5749200A (en) | 2001-01-09 |
| NO20016255L (no) | 2001-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2432085A1 (en) | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands | |
| AU4818000A (en) | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands | |
| ATE261448T1 (de) | Heteroaryl diazabicycloalkene, deren herstellung und verwendung | |
| ES2096312T3 (es) | Derivado de quinuclidina como antagonista de la sustancia p. | |
| MY107157A (en) | Quinuclidine derivatives. | |
| PT1200431E (pt) | Derivados de quinuclidina e sua utilizacao como ligandos de receptores muscarinicos m3 | |
| TR199902291T2 (xx) | �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller | |
| ES2195943T3 (es) | Compuestos heteroaromaticos biciclicos y triciclicos. | |
| TNSN99177A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION | |
| WO2002000623A3 (en) | Aryl fused substituted 4-oxy-pyridines | |
| MX9605218A (es) | Amidas aciclicas y ciclicas novedosas como mejoradores de liberacion de neurotransmisores. | |
| EE04905B1 (et) | Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks | |
| HUP0202534A2 (hu) | Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények | |
| ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
| DE60004671D1 (de) | Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung | |
| CA2263961A1 (en) | Cocaine receptor binding ligands | |
| NO20016255D0 (no) | Kromeno[4,3,2-de]isoquinoline som potente dopamineresepter ligander | |
| ATE261443T1 (de) | 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen | |
| DE69925160D1 (de) | Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität | |
| PT1025101E (pt) | Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central | |
| PT1082116E (pt) | Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento | |
| HUP0004671A2 (hu) | 5-Szubsztituált-3-oxadiazolil-1,6-naftiridin-2(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| EP1172106A3 (en) | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists | |
| PT889044E (pt) | Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central | |
| TNSN00178A1 (en) | Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |